1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
The solicitation RFA-EY-21-002 is closed; this page is an informational overview of the AMD Integrative Biology Initiative, not the RFP itself.
Discovery of AMD Pathobiology using Patient-Derived Induced Pluripotent Stem Cell (iPSC)-derived Retinal Pigment Epithelium (RPE) (U01 Clinical Trial Not Allowed) is sponsored by National Institutes of Health (NIH) - National Eye Institute (NEI). This funding opportunity announcement (FOA) seeks research projects focused on understanding the pathobiology of Age-related Macular Degeneration (AMD) using patient-derived induced pluripotent stem cell (iPSC)-derived Retinal Pigment Epithelium (RPE).
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
AMD Integrative Biology Initiative | National Eye Institute AMD Integrative Biology Initiative Closed.
Age-related Macular Degeneration (AMD) Integrative Biology Initiative: Discovery of AMD Pathobiology using Patient-Derived Induced Pluripotent Stem Cell (iPSC)-derived Retinal Pigment Epithelium (RPE) (U01 Clinical Trial Not Allowed) This funding opportunity aims to support collaborative studies of a unique resource of patient-derived induced pluripotent stem cell (iPSC) lines generated by the NEI age-related macular degeneration (AMD) Integrative Biology Initiative.
The goal of this FOA is to determine if these iPSC-derived cell lines can be used to discover the underlying pathophysiology of AMD. Collaborative effort is highly encouraged with investigators bringing in the needed areas of expertise for successful projects.
Newly Launched AMD Integrative Biology Initiative - A Community Resource of Patient iPSC lines In a bold effort to build on the AREDS2 investments, the NEI is working to: correlate clinical AMD disease phenotypes in a cellular model with patient genotype and imaging information in the newly created AMD Integrative Biology Initiative, make this Initiative available to the research community with induced pluripotent stem cells (iPSCs) derived from AREDS2 participants with specific genetic risk factors for AMD, and cover a cohort of 73 AREDS2 patients (chosen based on known AMD risk alleles) in this undertaking that is done in partnership with the New York Stem Cell Foundation Research Institute (NYSCF).
There are now 60 iPSC lines now available from NYSCF and the accompanying genomic and phenotypic data will be available to the research community later this year. You can view this data NEI EyePSC page and it will be updated as new information is posted. Isogenic control lines in which the risk alleles have been corrected will be available next year.
These iPSC lines are intended for research use and requestors will be required to submit a description of their research when requesting the lines. How do I get these iPSC lines? Contact NYSCF for the NEI Age-related Macular Degeneration Panel and include a brief statement of work on how you will use the lines.
Flow data for first 11 iPSC lines with high prevalence risk alleles The first 11 iPSC lines have been validated in Dr. Kapil Bharti’s lab for differentiation to RPE. Flow cytometry data using MITF and TYRP1 as markers are available upon request. Isogenic control lines in which the risk alleles have been corrected will be available later this year for the first 11 iPSC lines with high-prevalence risk alleles .
For acknowledgment of this data, please note Ruchi Sharma, Devika Bose, Genqing Liang, Roba Dejene, and Kapil Bharti (all NEI) as originators of the data. Science Translational Medicine Research Article: Clinical-grade stem cell–derived retinal pigment epithelium patch rescues retinal degeneration in rodents and pigs Last updated: October 27, 2025
According to the current listing, eligibility includes: Public and State controlled institutions of higher education; Private institutions of higher education; others (see text field entitled 'Additional Information on Eligibility' for clarification). Confirm the full requirements in the official notice before applying.
The current listing shows up to $250,000. Verify award ceilings, matching requirements, and allowable costs in the official notice.
Discovery of AMD Pathobiology using Patient-Derived Induced Pluripotent Stem Cell (iPSC)-derived Retinal Pigment Epithelium (RPE) (U01 Clinical Trial Not Allowed) is funded by National Institutes of Health (NIH) - National Eye Institute (NEI). Verify program details on the funder's official page before applying.
Yes — this listing is flagged as national in scope, so applicants across the U.S. may apply, subject to the sponsor's other eligibility criteria.
Start with the full solicitation document linked on this page — it contains the submission instructions and required forms.
PA-27-037 consolidates the Predoctoral to Postdoctoral Transition Award into a single parent announcement across 20 NIH components, with the next deadline December 8, 2026. The eligibility gate is not the science — it is a mandatory change of institution and mentor between the F99 and K00 phases.
Read articleA draft executive order would have put OMB Director Russell Vought on a commission with final say over NIH awards after peer review. Sen. Collins killed it by pointing at a provision Congress already passed. Here is what the episode teaches applicants about the December 11 cliff.
Read articlePA-27-034, PA-27-035 and PA-27-036 replace the institute-specific R25 announcements that research education programs have been built around for a decade. NCI, NIDA and NIGMS have already expired theirs early. Here is what the consolidation actually changes: an 8% indirect cost ceiling, a US-citizens-and-permanent-residents participant rule, a cooperative agreement variant that only exists on one of the three, and no clinical-trial-allowed companion anywhere.
Read article